FIELD: medicine.
SUBSTANCE: object 1 is the use of a strain of Ruminococcus faecis for the prevention, relief of symptoms or therapeutic effect on non-alcoholic fatty liver disease in a subject having insulin resistance, wherein the non-alcoholic fatty liver disease has one or more characteristics such as an increased concentration of ALT in the blood, an increased concentration of AST in the blood, decreased concentration of secondary bile acids in the cecum, increased expression of fibrotic genes Collal, Timp1 and α-SMA and increased liver weight to body weight ratio. Object 2 is a method of preventing, relieving symptoms or therapeutically affecting non-alcoholic fatty liver disease with the above characteristics in a subject with insulin resistance, comprising orally administering a strain of Ruminococcus faecis to the said subject.
EFFECT: therapeutic effect of the Ruminococcus faecis strain on non-alcoholic fatty liver disease in a subject with insulin resistance.
4 cl, 5 dwg, 5 tbl, 5 ex
Title | Year | Author | Number |
---|---|---|---|
KIT FOR PREDICTION OR DIAGNOSTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE AND A METHOD OF DIAGNOSTICS OF NON-ALCOHOLIC FATTY LIVER DISEASE | 2020 |
|
RU2800086C1 |
NEW HEPATOPROTECTIVE AGENTS AND METHODS FOR PREPARING THEM | 2023 |
|
RU2815370C1 |
COMPOSITION FOR PREVENTING OR TREATING FATTY LIVER DISEASES | 2015 |
|
RU2664696C2 |
NALMEFEN, NALTREXONE OR DERIVATIVES THEREOF FOR USE IN TREATING (NON)-ALCOHOLIC STEATOHEPATITIS OR NON-ALCOHOLIC FATTY LIVER DISEASE | 2017 |
|
RU2717677C1 |
METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE ACCOMPANYING METABOLIC SYNDROME | 2018 |
|
RU2686042C1 |
METHOD OF TREATING NON-ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH METABOLIC SYNDROME WITH VITAMIN D DEFICIENCY | 2018 |
|
RU2694842C1 |
METHOD OF REGENERATING LIVER HEPATOCYTES WITH PHOSPHOLIPIDS | 2014 |
|
RU2563138C1 |
COMPOSITION FOR PREVENTING, IMPROVING OR TREATING OBESITY OR FATTY LIVER DISEASE CONTAINING LEUCONOSTOC CITREUM WiKim0104 | 2020 |
|
RU2816754C2 |
MEANS FOR NON-ALCOHOLIC FATTY LIVER DISEASE TREATMENT AND PREVENTION | 2016 |
|
RU2644282C2 |
THERAPEUTIC AGENT FOR LIVER DISEASES | 2018 |
|
RU2723686C1 |
Authors
Dates
2023-12-27—Published
2020-07-30—Filed